Business
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
(NewsDirect) Toronto, ON, October 13, 2013 ( PlatoData via 500NewsWire) -- In the United ...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics (NASDAQ: CRDL)\nAdvancements in Therapies for Inflammatory Heart Diseases\n \n \n (NewsDirect)\n \n \n \n Toronto, ON,\nOctober 13, 2013 (\n \n PlatoData\n \n via\n500NewsWire) -- In the United States, heart disease accounts for a\nsignificant number of deaths every year, with cardiovascular disease\nbeing the primary concern. Factors like lifestyle choices and\nunforeseen circumstances contribute to its prevalence.\n \n \n Myocarditis\n(inflammation of the heart muscle) and pericarditis (inflammation of\nthe heart's lining) are two inflammatory heart conditions\nprimarily linked to immunological reactions from viral infections and\nmRNA vaccines. Though considered rare, awareness of these conditions\nis growing, especially among younger populations.\n \n \n Recent research in\nScience Immunology highlighted an increase in cytokine production\nleading to myocarditis in individuals after their second dose of\ncertain mRNA vaccines. The rise in heart-related incidents among young\nathletes in recent years is an area of growing concern. While adverse\nreactions to vaccines have historical precedence, the link between\nmyocarditis and certain vaccines is an area of ongoing study.\n \n \n The treatment landscape\nin the U.S. presents challenges. Available treatments can be costly\nand are often determined based on the severity of the case. Many\ninstances of heart inflammation, while initially mild, can escalate if\nmisdiagnosed or undetected, leading to significant\ncomplications.\n \n \n Cardiol Therapeutics, Inc. has been proactive in addressing\nthese concerns. The company has developed two formulations,\nCardiolRx™ and CRD-38, to address the challenges posed by\ninflammatory heart diseases. CardiolRx™ is believed to reduce\ninflammatory cell activation and the subsequent production of\ninflammatory cytokines. Additionally, this formulation has the\npotential to minimize scar tissue formation in the heart muscle.\n \n \n A notable feature of\nCardiol’s formulations is the use of cannabidiol as the primary\nactive ingredient. Their research initiatives position them at the\nforefront of treatment development for myocarditis and other severe\nheart conditions.\n \n \n Increased awareness around myocarditis due to potential\nvaccine-related complications has accelerated research efforts in t...